INTRODUCTION: NeuroQuant® is a recently developed, FDA-approved software program for measuring brain MRI volume in clinical settings. The aims of this study were as follows: (1) to examine the test-retest reliability of NeuroQuant®; (2) to test the hypothesis that patients with mild traumatic brain injury (TBI) would have abnormally rapid progressive brain atrophy; and (3) to test the hypothesis that progressive brain atrophy in patients with mild TBI would be associated with vocational outcome. METHODS: Sixteen patients with mild TBI were compared to 20 normal controls. Vocational outcome was assessed with the Glasgow Outcome Scale-Extended (GOSE) and Disability Rating Scale (DRS). RESULTS: NeuroQuant® showed high test-re-test reliability. Patients had abnormally rapid progressive atrophy in several brain regions and the rate of atrophy was associated with inability to return to work. CONCLUSIONS: NeuroQuant®, is a reliable and valid method for assessing the anatomic effects of TBI. Progression of atrophy may continue for years after injury, even in patients with mild TBI.
INTRODUCTION: NeuroQuant® is a recently developed, FDA-approved software program for measuring brain MRI volume in clinical settings. The aims of this study were as follows: (1) to examine the test-retest reliability of NeuroQuant®; (2) to test the hypothesis that patients with mild traumatic brain injury (TBI) would have abnormally rapid progressive brain atrophy; and (3) to test the hypothesis that progressive brain atrophy in patients with mild TBI would be associated with vocational outcome. METHODS: Sixteen patients with mild TBI were compared to 20 normal controls. Vocational outcome was assessed with the Glasgow Outcome Scale-Extended (GOSE) and Disability Rating Scale (DRS). RESULTS: NeuroQuant® showed high test-re-test reliability. Patients had abnormally rapid progressive atrophy in several brain regions and the rate of atrophy was associated with inability to return to work. CONCLUSIONS: NeuroQuant®, is a reliable and valid method for assessing the anatomic effects of TBI. Progression of atrophy may continue for years after injury, even in patients with mild TBI.
Authors: Timothy B Meier; Patrick S F Bellgowan; Maurizio Bergamino; Josef M Ling; Andrew R Mayer Journal: J Neurotrauma Date: 2015-08-17 Impact factor: 5.269
Authors: Lyubomir Zagorchev; Carsten Meyer; Thomas Stehle; Fabian Wenzel; Stewart Young; Jochen Peters; Juergen Weese; Keith Paulsen; Matthew Garlinghouse; James Ford; Robert Roth; Laura Flashman; Thomas McAllister Journal: J Neurotrauma Date: 2015-07-23 Impact factor: 5.269
Authors: Erin D Bigler; Tracy J Abildskov; Barry Eggleston; Brian A Taylor; David F Tate; Jo Ann Petrie; Mary R Newsome; Randall S Scheibel; Harvey Levin; William C Walker; Naomi Goodrich-Hunsaker; Nicholas J Tustison; James R Stone; Andrew R Mayer; Timothy D Duncan; Gerry E York; Elisabeth A Wilde Journal: Int J Methods Psychiatr Res Date: 2019-05-23 Impact factor: 4.035